Examkin

Soru

Zorluk: KolayRheumatology and Immunology

Match each autoantibody to its most characteristic associated rheumatologic condition or clinical feature.

  • Anti-cyclic citrullinated peptide (anti-CCP) antibodiesHighly specific for Rheumatoid Arthritis; indicates a higher likelihood of aggressive disease.
  • Anti-double-stranded DNA (anti-dsDNA) antibodiesHighly specific for Systemic Lupus Erythematosus; titer correlates with disease activity and lupus nephritis.
  • Anti-centromere antibodiesAssociated with Limited Cutaneous Systemic Sclerosis; indicates higher risk for pulmonary arterial hypertension.
  • Anti-Scl-70 (anti-topoisomerase I) antibodiesAssociated with Diffuse Cutaneous Systemic Sclerosis; indicates higher risk for interstitial lung disease.

Cevap

The correct matches are: Anti-CCP with Rheumatoid Arthritis; Anti-dsDNA with Systemic Lupus Erythematosus; Anti-centromere with Limited Cutaneous Systemic Sclerosis; and Anti-Scl-70 with Diffuse Cutaneous Systemic Sclerosis.
Autoantibodies serve as crucial diagnostic and prognostic markers in rheumatology. Anti-CCP is highly specific for Rheumatoid Arthritis. Anti-dsDNA is specific for SLE and tracks disease activity. Anti-centromere and anti-Scl-70 help differentiate between limited and diffuse cutaneous systemic sclerosis, respectively, with each carrying distinct clinical features and visceral risks.

Adım Adım Çözüm

1
Identify the disease association for anti-CCP antibodies.
Matches with Rheumatoid Arthritis.
Anti-CCP is the most specific serological marker for RA.
2
Identify the disease association for anti-dsDNA antibodies.
Matches with Systemic Lupus Erythematosus.
Anti-dsDNA is specific to SLE and its titer correlates with disease flares and renal involvement.
3
Identify the disease association for anti-centromere antibodies.
Matches with Limited Cutaneous Systemic Sclerosis.
It is the defining serological feature of limited systemic sclerosis (CREST syndrome).
4
Identify the disease association for anti-Scl-70 antibodies.
Matches with Diffuse Cutaneous Systemic Sclerosis.
It distinguishes the diffuse form of systemic sclerosis from the limited form and predicts a higher risk of interstitial lung disease.

Anahtar Kavram

Clinical utility of specific autoantibodies in the diagnosis and prognostication of systemic autoimmune diseases.
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru